眼科用医薬品の市場規模、シェア、成長分析、疾患別、薬剤クラス別、投薬別、投与方法別、製品別、地域別 - 産業予測 2025年～2032年

眼科用医薬品市場規模は2023年に346億米ドルと評価され、2024年の366億1,000万米ドルから2032年には574億7,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは5.8%で推移する見通しです。

眼科用医薬品市場は、革新的な治療法を生み出すための研究開発の強化や、業界リーダーによる戦略的な取り組みによって大きな成長が見込まれています。世界では約22億人が視力障害を経験しており、その多くは予防可能なケースであることから、同市場の可能性は膨大です。加齢に伴う視力問題が主な要因であり、近視だけでも推定2,440億米ドルの費用がかかるなど、経済的負担が大きくなっています。COVID-19パンデミックは眼科サービスの低下を招いたが、ワクチンの入手可能性が高まったため、市場は回復すると予想されています。アルコンのような企業は研究開発投資を強化しており、戦略的買収やFDAの承認によって、企業はこの成長機会を生かすことができるようになり、眼科治療の堅調な将来を確実なものにしています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ

眼科用医薬品市場規模：疾患別& CAGR（2025-2032）

• 市場概要
• 目のアレルギー
• 眼感染症
• 緑内障
• 網膜疾患
• ドライアイ
• その他

眼科用医薬品市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• 抗アレルギー
• 抗炎症
• 緑内障治療薬
• 抗VEGF薬

眼科用医薬品市場規模：投薬別& CAGR（2025-2032）

• 市場概要
• アイソリューションズ
• ゲル
• カプセル
• 目薬
• 軟膏

眼科用医薬品市場規模：投与方法別& CAGR（2025-2032）

• 市場概要
• 全身的
• 局所的
• 局所眼科

眼科用医薬品市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 処方薬
• 市販薬

眼科用医薬品市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Novartis AG（Switzerland）
• Johnson & Johnson Vision（United States）
• Alcon Inc.（Switzerland）
• AbbVie Inc.（United States）
• Bausch Health Companies Inc.（Canada）
• Regeneron Pharmaceuticals Inc.（United States）
• Pfizer Inc.（United States）
• Santen Pharmaceutical Co. Ltd.（Japan）
• Merck & Co., Inc.（United States）
• Bayer AG（Germany）
• Coherus Biosciences, Inc.（United States）
• Genentech, Inc.（United States）
• Sun Pharmaceutical Industries Ltd.（India）
• Aerie Pharmaceuticals（United States）
• Rohto Pharmaceutical Co., Ltd.（Japan）
• Menicon Co., Ltd.（Japan）
• Ellex Medical Lasers Ltd.（Australia）
• Topcon Corporation（Japan）
• Veeva Systems Inc.（United States）
• Recipharm AB（Sweden）

結論と提言

Ophthalmic Drugs Market size was valued at USD 34.6 billion in 2023 and is poised to grow from USD 36.61 billion in 2024 to USD 57.47 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

The ophthalmic drugs market is poised for significant growth driven by intensified research and development efforts to create innovative treatments and strategic initiatives from industry leaders. With around 2.2 billion people globally experiencing vision impairment, many cases being preventable, the market's potential is vast. Age-related vision issues are the primary driver, contributing to a substantial economic burden, such as the estimated USD 244 billion cost linked to myopia alone. Although the COVID-19 pandemic caused a decline in ophthalmic services, the market is expected to rebound due to increased vaccine availability. Companies like Alcon are ramping up R&D investments, and strategic acquisitions and FDA approvals are further positioning firms to capitalize on this growth opportunity, ensuring a robust future for ophthalmic therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Ophthalmic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Ophthalmic Drugs Market Segments Analysis

Global Ophthalmic Drugs Market is segmented by Disease, Drug Class, Dosage, Administration, Product and region. Based on Disease, the market is segmented into Eye Allergy, Eye Infection, Glaucoma, Retinal Disorders, Dry Eye and Others. Based on Drug Class, the market is segmented into Anti-Allergy, Anti-Inflammatory, Antiglaucoma and Anti-VEGF Agents. Based on Dosage, the market is segmented into Eye Solutions, Gels, Capsules, Eye Drops and Ointments. Based on Administration, the market is segmented into Systematic, Topical and Local Ocular. Based on Product, the market is segmented into Prescription Drugs and Over-the-Counter-Drugs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Ophthalmic Drugs Market

The ophthalmic drugs market is predominantly driven by the increasing prevalence of various eye conditions, including cataracts, glaucoma, and macular degeneration. This surge can be attributed to several factors, such as the aging population, shifts in lifestyle habits, and a rise in chronic illnesses. As more individuals experience these eye-related issues, the demand for effective ophthalmic medications is escalating. Consequently, this trend is fostering growth within the market as healthcare providers and pharmaceutical companies focus on developing and delivering innovative treatments to meet the needs of patients affected by these prevalent eye diseases.

Restraints in the Ophthalmic Drugs Market

The ophthalmic drugs market faces a significant restraint due to stringent regulatory requirements governing drug approval and market entry. These complex and often protracted regulatory procedures create hurdles for companies, leading to delays in product launches and potentially stifling market growth. As manufacturers strive to navigate these rigorous guidelines, the extended timelines and increased costs associated with compliance can impede their ability to bring innovative treatments to market efficiently. Consequently, the challenges linked to regulatory scrutiny can act as deterrents, affecting overall competitiveness and limiting opportunities within the ophthalmic drugs sector.

Market Trends of the Ophthalmic Drugs Market

The ophthalmic drugs market is increasingly leaning towards personalized medicine, a trend driven by the need for treatments that cater to individual patient profiles and unique ocular conditions. With advancements in genomic research and the rise of precision medicine, pharmaceutical companies are developing targeted therapies that enhance therapeutic efficacy and boost patient satisfaction. This shift not only improves clinical outcomes but also fosters a more patient-centric approach in ophthalmology. As regulatory bodies adapt to these innovations, the market is expected to see a surge in the adoption of customized treatment plans that align with the characteristics of specific patient populations, further transforming the landscape of eye care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Ophthalmic Drugs Market Size by Disease & CAGR (2025-2032)

• Market Overview
• Eye Allergy
• Eye Infection
• Glaucoma
• Retinal Disorders
• Dry Eye
• Others

Global Ophthalmic Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anti-Allergy
• Anti-Inflammatory
• Antiglaucoma
• Anti-VEGF Agents

Global Ophthalmic Drugs Market Size by Dosage & CAGR (2025-2032)

• Market Overview
• Eye Solutions
• Gels
• Capsules
• Eye Drops
• Ointments

Global Ophthalmic Drugs Market Size by Administration & CAGR (2025-2032)

• Market Overview
• Systematic
• Topical
• Local Ocular

Global Ophthalmic Drugs Market Size by Product & CAGR (2025-2032)

• Market Overview
• Prescription Drugs
• Over-the-Counter-Drugs

Global Ophthalmic Drugs Market Size & CAGR (2025-2032)

• North America (Disease, Drug Class, Dosage, Administration, Product)
  • US
  • Canada
• Europe (Disease, Drug Class, Dosage, Administration, Product)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease, Drug Class, Dosage, Administration, Product)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease, Drug Class, Dosage, Administration, Product)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease, Drug Class, Dosage, Administration, Product)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Vision (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co. Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus Biosciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerie Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rohto Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Menicon Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ellex Medical Lasers Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Topcon Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veeva Systems Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations